135 related articles for article (PubMed ID: 35660936)
1. Management of patients susceptible to malignant hyperthermia: A surgeon's perspective.
Carlson KJ; Sun SA; Swan C; Koenig M; Derkay CS
Int J Pediatr Otorhinolaryngol; 2022 Aug; 159():111187. PubMed ID: 35660936
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
Serfas KD; Bose D; Patel L; Wrogemann K; Phillips MS; MacLennan DH; Greenberg CR
Anesthesiology; 1996 Feb; 84(2):322-9. PubMed ID: 8602662
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors of the contracture test for diagnosing malignant hyperthermia in a Brazilian population sample: a retrospective observational study.
de Mello JM; Andrade PV; Santos JM; Oliveira ASB; Vainzof M; do Amaral JLG; Almeida da Silva HC
Braz J Anesthesiol; 2023; 73(2):145-152. PubMed ID: 35835312
[TBL] [Abstract][Full Text] [Related]
4. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests].
Mortier W; Breucking E
Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201
[TBL] [Abstract][Full Text] [Related]
5. Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility.
Wappler F; Anetseder M; Baur CP; Censier K; Doetsch S; Felleiter P; Fiege M; Fricker R; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Hopkins PM; Klingler W; Lehmann-Horn F; Nivoche Y; Tegazzin V; Tzanova I; Urwyler A; Weisshorn R; Schulte am Esch J
Eur J Anaesthesiol; 2003 Jul; 20(7):528-36. PubMed ID: 12884985
[TBL] [Abstract][Full Text] [Related]
6. A Single-Center Retrospective Review of Patients with Suspected Malignant Hyperthermia Susceptibility.
Edwards C; Dooley FC; Gonzalez S; Austin TM; Gravenstein N
Cureus; 2023 Sep; 15(9):e44661. PubMed ID: 37799222
[TBL] [Abstract][Full Text] [Related]
7. Safety of general anesthesia in patients previously tested negative for malignant hyperthermia susceptibility.
Allen GC; Rosenberg H; Fletcher JE
Anesthesiology; 1990 Apr; 72(4):619-22. PubMed ID: 2321777
[TBL] [Abstract][Full Text] [Related]
8. An analysis of the predictive probability of the in vitro contracture test for determining susceptibility to malignant hyperthermia.
Hopkins PM; Ellis FR; Halsall PJ; Stewart AD
Anesth Analg; 1997 Mar; 84(3):648-56. PubMed ID: 9052318
[TBL] [Abstract][Full Text] [Related]
9. A blinded comparison of noninvasive, in vivo phosphorus nuclear magnetic resonance spectroscopy and the in vitro halothane/caffeine contracture test in the evaluation of malignant hyperthermia susceptibility.
Olgin J; Rosenberg H; Allen G; Seestedt R; Chance B
Anesth Analg; 1991 Jan; 72(1):36-47. PubMed ID: 1984374
[TBL] [Abstract][Full Text] [Related]
10. Genetic effects on the variability of the halothane and caffeine muscle contracture tests.
Urwyler A; Censier K; Kaufmann MA; Drewe J
Anesthesiology; 1994 Jun; 80(6):1287-95. PubMed ID: 8010475
[TBL] [Abstract][Full Text] [Related]
11. Sevoflurane is less sensitive than halothane for in vitro detection of malignant hyperthermia susceptibility.
Johannsen S; Klingler W; Schneiderbanger D; Heiderich S; Roewer N; Schuster F
Acta Anaesthesiol Scand; 2013 Oct; 57(9):1161-6. PubMed ID: 23957432
[TBL] [Abstract][Full Text] [Related]
12. Malignant Hyperthermia Susceptibility and Fitness for Duty.
Lee MA; McGlinch EB; McGlinch MC; Capacchione JF
Mil Med; 2017 Mar; 182(3):e1854-e1857. PubMed ID: 28290972
[TBL] [Abstract][Full Text] [Related]
13. Effect of cocaine on the contracture response to 1% halothane in patients undergoing diagnostic muscle biopsy for malignant hyperthermia.
Sato N; Brum JM; Mitsumoto H; DeBoer GE
Can J Anaesth; 1995 Feb; 42(2):158-62. PubMed ID: 7720160
[TBL] [Abstract][Full Text] [Related]
14. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM
Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989
[TBL] [Abstract][Full Text] [Related]
15. Masseter muscle rigidity and malignant hyperthermia susceptibility in pediatric patients. An update on management and diagnosis.
O'Flynn RP; Shutack JG; Rosenberg H; Fletcher JE
Anesthesiology; 1994 Jun; 80(6):1228-33. PubMed ID: 8010468
[TBL] [Abstract][Full Text] [Related]
16. DNA testing for malignant hyperthermia: the reality and the dream.
Stowell KM
Anesth Analg; 2014 Feb; 118(2):397-406. PubMed ID: 24445638
[TBL] [Abstract][Full Text] [Related]
17. Is there a link between exertional heat stroke and susceptibility to malignant hyperthermia?
Sagui E; Montigon C; Abriat A; Jouvion A; Duron-Martinaud S; Canini F; Zagnoli F; Bendahan D; Figarella-Branger D; Brégigeon M; Brosset C
PLoS One; 2015; 10(8):e0135496. PubMed ID: 26258863
[TBL] [Abstract][Full Text] [Related]
18. Incidence of malignant hyperthermia reactions in 2,214 patients undergoing muscle biopsy.
Carr AS; Lerman J; Cunliffe M; McLeod ME; Britt BA
Can J Anaesth; 1995 Apr; 42(4):281-6. PubMed ID: 7788824
[TBL] [Abstract][Full Text] [Related]
19. Use of the caffeine-halothane contracture test for the diagnosis of malignant hyperthermia in Brazil.
Sudo RT; Cunha LB; Carmo PL; Matos AR; Trachez MM; Cardoso LA; Aguiar MI; Abreu AV; Zapata-Sudo G
Braz J Med Biol Res; 2010 Jun; 43(6):549-56. PubMed ID: 20464345
[TBL] [Abstract][Full Text] [Related]
20. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.
Ording H; Brancadoro V; Cozzolino S; Ellis FR; Glauber V; Gonano EF; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Kozak-Ribbens G; Kress H; Krivosic-Horber R; Lehmann-Horn F; Mortier W; Nivoche Y; Ranklev-Twetman E; Sigurdsson S; Snoeck M; Stieglitz P; Tegazzin V; Urwyler A; Wappler F
Acta Anaesthesiol Scand; 1997 Sep; 41(8):955-66. PubMed ID: 9311391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]